Why the study?
ADMA is an endogenous nitric oxide inhibitor involved in cardiovascular risk processes, prompting analysis of its correlation with anthropometric, glucose, lipid, and inflammatory parameters in obesity.
In obese subjects, ADMA levels are significantly correlated with cardiovascular risk parameters including fasting plasma glucose, HbA1c, and triglycerides.
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxideproduction and involved in various pathological processes, especially processes involvingcardiovascular risk. The purpose of this study was to analyze the correlation betweenADMA and anthropometric, glucose, lipid, and inflammatory parameters. The study wasanalyzed by a cross-sectional study of 45 obese subjects at H. Adam Malik Hospital. Bloodtests were carried out after 8-10 hours of fasting against cardiovascular risk: anthropometry(body weight, BMI, and WC), glucose (FPS, PPS, HbA1C, Fasting Insulin, and HOMA-IR), lipid (LDL-C, HDL-C, TG, and sd-LDL), and inflammation (ApoB and hs-CRP)parameters. The results showed of the 45 subjects, the average age was 41.69 ± 5.69 yearsold, and the average BMI was 33.09 ± 5.05 (Obesity I). ADMA was also found to becorrelated significantly with FPG, HBA1c, and TG parameters [r=-0.506, p=0.001; r=-0.334, p=0.013, dan r = -0.315. p=0.017, respectively]. In obesity, ADMA correlatedsignificantly with cardiovascular risk parameters: FPG, HbA1C, and TG.
No takes yet. Share an insight, caveat, or question.
Lindarto et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: